Enhancing the Butyrylcholinesterase Activity in HEK-293 Cell Line by Dual-Promoter Vector Decorated on Lipofectamine
Open Access
- 1 September 2020
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 14, 3589-3599
Abstract
Purpose: Human butyrylcholinesterase (BChE) serves as a bio scavenger to counteract organophosphate poisoning. It is also a potential drug candidate in several therapeutic fields. Therefore, in the present study, we constructed a new dual-promoter plasmid consisting of Cytomegalovirus (CMV) and human elongation factor 1α (EF-1α) promoters and transfected that into HEK-293 cells using Lipofectamine to enhance the BChE secretion. Methods: The new dual-promoter construction (pBudCE dual BChE) including two copies of the BChE gene was designed and transfected into cells by liposomal structures. The cloned plasmids were evaluated by enzyme digestion and gel electrophoresis analysis. Experimental groups were categorized into the cells transfected by pBudCE dual BChE (treatment), pCMV (positive control) vectors, and nontransfected cells (negative control). BChE gene expression was evaluated by qRT-PCR and the enzyme activity was assessed using modified Ellman’s method. The freeze-thaw process was carried out for analyzing the stability of the pBudCE dual BChE vector. Results: Validation examination of the cloned plasmids confirmed the successful cloning process. The gene expression level and Ellman’s method value in pBudCE dual BChE was higher than the other groups. CMV promoter has also increased the enzyme activity, although the difference was not significant compared with the control group. Interestingly, freeze-thaw cycles followed by several passages did not affect the enzyme activity. Conclusion: The designed construction with CMV and EF-1α promoters could increase BChE gene expression and the activity of the BChE enzyme in HEK-293 cell line. Large-scale production of BChE enzyme can be achieved by using dual-promoter plasmid construction compared to a single-promoter vector to be used in clinical trials.Keywords
This publication has 33 references indexed in Scilit:
- Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivoProceedings of the National Academy of Sciences, 2013
- Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible PromoterPLOS ONE, 2010
- Management of acute organophosphorus pesticide poisoningThe Lancet, 2008
- Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoningProceedings of the National Academy of Sciences, 2007
- Polyethylene glycosylation prolongs the circulatory stability of recombinant human butyrylcholinesteraseChemico-Biological Interactions, 2005
- Bioscavengers for the protection of humans against organophosphate toxicityChemico-Biological Interactions, 2005
- Estimation of the Upper Limit of Human Butyrylcholinesterase Dose Required for Protection against Organophosphates Toxicity: a Mathematically Based Toxicokinetic ModelToxicological Sciences, 2004
- Wild-Type and A328W Mutant Human Butyrylcholinesterase Tetramers Expressed in Chinese Hamster Ovary Cells Have a 16-Hour Half-Life in the Circulation and Protect Mice from Cocaine ToxicityThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugsDrug Development Research, 2000
- Half–life of plasma cholinesteraseActa Anaesthesiologica Scandinavica, 1988